연골 성형술 시장 : 점유율 분석, 업계 동향과 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the chondroplasty market size is expected to grow from USD 1.93 billion in 2025 to USD 2.06 billion in 2026 and is forecast to reach USD 2.86 billion by 2031 at 8.97% CAGR over 2026-2031.

This report is Segmented by Procedure Type, Anatomy, Surgical Approach, End User, Clinical Indication, Distribution Channel, and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Chondroplasty Market Trends and Insights

Rising Burden of Osteoarthritis and Focal Cartilage Defects

A 2024 PLOS ONE study reported that osteoarthritis affected 607 million people worldwide, which is expanding the patient pool for cartilage debridement procedures. The disease burden is moving beyond older patients because incidence has increased within the 30-60 working-age population. The World Health Organization's 2024 osteoarthritis fact sheet identifies knee osteoarthritis as the most common form of the disease, with 365 million people affected globally. This pattern keeps the knee central to the chondroplasty market because knee cartilage defects are often treated during arthroscopic care. The expected increase in hip osteoarthritis cases also supports demand for hip procedures. The chondroplasty market, therefore, has a broader demand base than one dependent on isolated sports injuries.

Growth in Sports-Related Knee, Shoulder, and Hip Injuries

Sports and recreational activities continue to create a sustained flow of knee, shoulder, and hip injuries that can involve cartilage damage. A February 2025 study published by Healio identified 6,689,422 shoulder injuries in emergency department cases, and 45.84% were linked to sports and recreation. A 2025 analysis in Knee Surgery, Sports Traumatology, Arthroscopy reported knee pathologies in 75.50% of 9,432 German arthroscopy registry entries, with meniscal lesions requiring resection as the largest diagnosis group. These conditions are commonly managed alongside cartilage treatment in the same arthroscopic procedure. Injury rates are also increasing among people aged 45-64, which combines acute injury demand with early degenerative joint care. This age group is more likely to favor procedures that preserve joint function and delay replacement surgery.

Variable Long-Term Durability of Fibrocartilage Repair

Chondroplasty can produce fibrocartilage rather than the hyaline cartilage found on healthy articular surfaces. Fibrocartilage does not provide the same long-term load distribution under repeated mechanical stress. A 2025 ISAKOS Congress abstract describing a 95-patient cohort reported reoperation rates of 31.80% for mechanical chondroplasty and 33.30% for radiofrequency ablation. The same cohort reported failure rates of 18.80% and 28.60%, respectively, at mean follow-up. These outcomes can limit confidence in chondroplasty as a definitive solution for some patients. The procedure may instead be used more often as a preparation step before scaffold-based or biologic cartilage repair.

Other drivers and restraints analyzed in the detailed report include:

1. Shift Toward Joint Preservation and Minimally Invasive Arthroscopy
2. Expansion of Outpatient Orthopedic and Sports Medicine Capacity
3. Uneven Reimbursement and Payer Evidence Requirements

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Arthroscopic shaving accounted for 33.18% of 2025 revenue and remained the largest procedure type in the chondroplasty market. Its established role in cartilage debridement supports use across a large installed base of conventional arthroscopy systems. The technique fits familiar operating workflows and can be used with a range of supporting instruments. Laser-assisted chondroplasty is forecast to expand at a 9.27% CAGR through 2031, making it the fastest-growing procedure type. A 2025 meta-analysis published in Lasers in Medical Science reported shorter operating times and higher patient satisfaction for laser-assisted orthopedic procedures than conventional alternatives. Radiofrequency ablation also remains relevant for outpatient providers who seek predictable tissue treatment and short procedure times.

Abrasion chondroplasty, tissue removal, and debridement continue to be used with meniscal and ligament repair procedures. These procedures retain a steady place in the chondroplasty market because many cartilage defects are identified during related arthroscopic surgery. Patellar repair and meniscal repair chondroplasty serve narrower clinical needs, including patellar tracking disorders and meniscal flap tears. Their contribution is more incremental than that of the leading procedure types. Across the segment, surgeons are seeking improved control over tissue depth and surface preparation. This preference supports instruments with depth feedback or pressure-sensing features. It may reduce reliance on basic mechanical shaving while directing spending toward energy-based and laser systems. The chondroplasty market size for laser-assisted procedures is expected to rise as facilities place more weight on precision and workflow efficiency.

The knee accounted for 67.11% of anatomy-segment revenue in 2025 and held the leading position in the chondroplasty market. Its position reflects the large global burden of knee osteoarthritis and the high number of knee sports injuries. Knee procedures also benefit from established arthroscopy pathways in hospitals and outpatient centers. Hip chondroplasty is forecast to grow at a 7.97% CAGR through 2031, ahead of other anatomy segments. Greater use of AI-assisted osteochondroplasty may improve confidence in cam-morphology correction during hip arthroscopy. More accurate resection can help surgeons avoid both incomplete correction and excessive bone removal.

Shoulder chondroplasty is associated with rotator cuff and labral pathologies that occur in sports-related injury care. Its procedure volume follows the continuing burden of shoulder injuries among active adults. Ankle chondroplasty serves patients with osteochondral talar lesions and is most relevant for younger and active patient groups. Wrist and elbow procedures address smaller populations, including elite athletes and workers in demanding manual roles. Small joints hold a smaller share of the chondroplasty market revenue but benefit from advances in miniaturized arthroscopy tools. Knee and hip procedures are expected to account for a larger share of biologic adjunct use as repair options develop. Manufacturers with anatomy-specific tips and depth-control features can be better aligned with this shift. The chondroplasty market can therefore see more value move toward specialized rather than general-purpose instruments.

Complete Report Scope:

• By Procedure Type
  • Arthroscopic Shaving
  • Abrasion Chondroplasty
  • Radiofrequency Ablation Chondroplasty
  • Patellar Chondroplasty
  • Meniscal Repair Chondroplasty
  • Tissue Removal and Debridement
  • Laser-Assisted Chondroplasty
  • Others
• By Anatomy
  • Knee
  • Shoulder
  • Hip
  • Ankle
  • Wrist and Elbow
  • Other Small-Joint Anatomy
• By Surgical Approach
  • Conventional Arthroscopy
  • Robotic-Assisted Arthroscopy
  • Image-Guided Arthroscopy
  • Open or Mini-Open Chondroplasty
  • Others
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Orthopaedic and Sports-Medicine Clinics
  • Academic and Research Institutes
  • Others
• By Clinical Indication
  • Focal Chondral Lesions
  • Osteochondritis Dissecans
  • Meniscal and Chondral Flap Tears
  • Early-Stage Osteoarthritis
  • Sports-Related Cartilage Injury
  • Post-Traumatic Cartilage Damage
  • Others
• By Distribution Channel
  • Direct Sales
  • Distributors
  • Group Purchasing Organizations and Integrated Delivery Networks
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America held 39.67% of revenue in 2025 and represented the largest geographic share of the chondroplasty market. The region has a mature reimbursement structure, high specialist density, and widespread use of orthopedic ambulatory surgical centers. In 2026, the removal of 266 musculoskeletal procedures from the Medicare inpatient-only list further supports outpatient case migration. The United States accounts for most regional revenue because it has a large installed base of radiofrequency ablation and laser systems. Vericel reported 30.00% year-on-year revenue growth for MACI to USD 56.40 million in the first quarter of 2026. This supports the broader joint-preservation pathway that includes surface preparation and cartilage treatment.

Europe remains an important regional contributor to the chondroplasty market, led by Germany, the United Kingdom, France, Italy, and Spain. Germany expanded its outpatient arthroscopy procedure list in January 2026, reducing reliance on inpatient treatment for knee arthroscopy. From July 2026, the country introduced a dedicated arthroscopy payment section with a 5.00% fee increase for relevant specialist procedures. The United Kingdom uses procurement frameworks and medical device access requirements that influence equipment adoption. France, Italy, and Spain have solid procedure volumes but use evidence-based coverage assessments that can slow uptake of premium devices. Poland and the Nordic countries are increasing their contribution as specialist capacity and private health investment develop.

Asia-Pacific is forecast to grow at a 8.23% CAGR through 2031 and is the fastest-growing region in the chondroplasty market. A 2024 PLOS ONE study reported 158 million prevalent osteoarthritis cases in East Asia in 2021, while high-income Asia-Pacific had the highest global age-standardized prevalence rate. Japan and South Korea are innovation-oriented markets that have complex reimbursement systems and active interest in regenerative care. China has advanced private hospitals in major cities, while wider adoption depends on regulatory approval and procurement catalog inclusion. India is centered on private hospitals in metropolitan areas, where price sensitivity and financing affect capital equipment placements. Middle East and Africa and South America are smaller regional contributors, with the Gulf Cooperation Council countries and Brazil as their primary access points. Medical tourism and private orthopedic hospital growth support demand in these emerging areas.

1. Arthrex
2. Stryker
3. Smiths Group
4. Zimmer Biomet
5. Johnson & Johnson
6. Conmed
7. Medtronic
8. B. Braun
9. Olympus
10. Karl Storz
11. Richard Wolf
12. Vericel
13. Anika Therapeutics
14. Geistlich Pharma
15. Regentis Biomaterials Ltd.
16. Bioventus
17. Episurf Medical
18. Trice Medical
19. Enovis Corporation
20. Exactech
21. NuOrtho Surgical, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Burden of Osteoarthritis and Focal Cartilage Defects
  • 4.2.2 Growth in Sports-Related Knee, Shoulder, and Hip Injuries
  • 4.2.3 Shift Toward Joint Preservation and Minimally Invasive Arthroscopy
  • 4.2.4 Expansion of Outpatient Orthopaedic and Sports-Medicine Capacity
  • 4.2.5 Procedure Standardization Through Depth-Controlled Microdrilling and RF Ablation
  • 4.2.6 Surgeon Demand for Single-Stage, Off-the-Shelf Cartilage Repair Adjuncts
• 4.3 Market Restraints
  • 4.3.1 Variable Long-Term Durability of Fibrocartilage Repair
  • 4.3.2 Uneven Reimbursement and Payer Evidence Requirements
  • 4.3.3 Subchondral-Bone Injury Risk From Inconsistent Debridement Depth
  • 4.3.4 Training, Case-Volume, and Capital-Equipment Barriers in Emerging Markets
• 4.4 Supply Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Intensity of Competitive Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Procedure Type
  • 5.1.1 Arthroscopic Shaving
  • 5.1.2 Abrasion Chondroplasty
  • 5.1.3 Radiofrequency Ablation Chondroplasty
  • 5.1.4 Patellar Chondroplasty
  • 5.1.5 Meniscal Repair Chondroplasty
  • 5.1.6 Tissue Removal and Debridement
  • 5.1.7 Laser-Assisted Chondroplasty
  • 5.1.8 Others
• 5.2 By Anatomy
  • 5.2.1 Knee
  • 5.2.2 Shoulder
  • 5.2.3 Hip
  • 5.2.4 Ankle
  • 5.2.5 Wrist and Elbow
  • 5.2.6 Other Small-Joint Anatomy
• 5.3 By Surgical Approach
  • 5.3.1 Conventional Arthroscopy
  • 5.3.2 Robotic-Assisted Arthroscopy
  • 5.3.3 Image-Guided Arthroscopy
  • 5.3.4 Open or Mini-Open Chondroplasty
  • 5.3.5 Others
• 5.4 By End User
  • 5.4.1 Hospitals
  • 5.4.2 Ambulatory Surgical Centers
  • 5.4.3 Orthopaedic and Sports-Medicine Clinics
  • 5.4.4 Academic and Research Institutes
  • 5.4.5 Others
• 5.5 By Clinical Indication
  • 5.5.1 Focal Chondral Lesions
  • 5.5.2 Osteochondritis Dissecans
  • 5.5.3 Meniscal and Chondral Flap Tears
  • 5.5.4 Early-Stage Osteoarthritis
  • 5.5.5 Sports-Related Cartilage Injury
  • 5.5.6 Post-Traumatic Cartilage Damage
  • 5.5.7 Others
• 5.6 By Distribution Channel
  • 5.6.1 Direct Sales
  • 5.6.2 Distributors
  • 5.6.3 Group Purchasing Organizations and Integrated Delivery Networks
  • 5.6.4 Others
• 5.7 By Geography
  • 5.7.1 North America
    • 5.7.1.1 United States
    • 5.7.1.2 Canada
    • 5.7.1.3 Mexico
  • 5.7.2 Europe
    • 5.7.2.1 Germany
    • 5.7.2.2 United Kingdom
    • 5.7.2.3 France
    • 5.7.2.4 Italy
    • 5.7.2.5 Spain
    • 5.7.2.6 Rest of Europe
  • 5.7.3 Asia-Pacific
    • 5.7.3.1 China
    • 5.7.3.2 Japan
    • 5.7.3.3 India
    • 5.7.3.4 Australia
    • 5.7.3.5 South Korea
    • 5.7.3.6 Rest of Asia-Pacific
  • 5.7.4 Middle East and Africa
    • 5.7.4.1 GCC
    • 5.7.4.2 South Africa
    • 5.7.4.3 Rest of Middle East and Africa
  • 5.7.5 South America
    • 5.7.5.1 Brazil
    • 5.7.5.2 Argentina
    • 5.7.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments)
  • 6.3.1 Arthrex, Inc.
  • 6.3.2 Stryker Corporation
  • 6.3.3 Smith & Nephew plc
  • 6.3.4 Zimmer Biomet Holdings, Inc.
  • 6.3.5 Johnson & Johnson
  • 6.3.6 CONMED Corporation
  • 6.3.7 Medtronic plc
  • 6.3.8 B. Braun Melsungen AG
  • 6.3.9 Olympus Corporation
  • 6.3.10 KARL STORZ SE & Co. KG
  • 6.3.11 Richard Wolf GmbH
  • 6.3.12 Vericel Corporation
  • 6.3.13 Anika Therapeutics, Inc.
  • 6.3.14 Geistlich Pharma AG
  • 6.3.15 Regentis Biomaterials Ltd.
  • 6.3.16 Bioventus LLC
  • 6.3.17 Episurf Medical
  • 6.3.18 Trice Medical
  • 6.3.19 Enovis Corporation
  • 6.3.20 Exactech, Inc.
  • 6.3.21 NuOrtho Surgical, Inc.

7 Market Opportunities & Future Outlook

• 7.1 White-Space and Unmet-Need Assessment